Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients

A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among high-risk cancer patients undergoing chemotherapy treatment using anthracyclines, according to preliminary late-breaking science presented today at the American Heart Association’s Scientific Sessions 2024.

Can iTeos and GSK solve TIGIT’s troubles?

Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He

September 12, 2024

New epigenetic clocks distinguish aging causes and effects

What causes us to age? New “clocks” developed by researchers may help point to the answers. Investigators from Brigham and Women’s Hospital, a founding member

February 15, 2024

Colorado dropped Medicaid enrollees as red states have, alarming advocates for the poor

Colorado stands out among the 10 states that have disenrolled the highest share of Medicaid beneficiaries since the U.S. government lifted a pandemic-era restriction on

July 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.